Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for Elvitegravir

    Client Email Product

    Elvitegravir

    APIs // Active Pharmaceutical Ingredients

    INTERMEDIATES

    DOSSIERs // Finished Dosage Formulations

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    DIGITAL CONTENT

    PharmaCompass
    Related ProductsRelated Products
    API SUPPLIERS
    API Suppliers

    API Suppliers

    14
    US DMFs Filed

    US DMFs Filed

    7
    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    0

    Other Certificates

    Other Certificates

    4
    Other Suppliers

    Other Suppliers

    7
    API REF. PRICE (USD / KG)

    0

    API Market Place

    1
    INTERMEDIATES
    1
    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    4
    Europe

    Europe

    4
    Canada

    Canada

    2
    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Uploaded Dossiers

    Uploaded Dossiers

    0

    GLOBAL SALES (USD Million)

    U.S. Medicaid

    0

    Annual Reports

    4,624.00

    FDF Market Place

    0

    EXCIPIENTS
    122
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    50

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    4

    News

    16
    REF STANDARD

    EDQM

    0

    USP

    0

    JP

    0

    Other Listed Suppliers

    0

    SERVICES

    0

    left grey arrow
    right gray arrow
    • TABLET;ORAL - 150MG
    • TABLET;ORAL - 85MG
    • TABLET;ORAL - 150MG;150MG;200MG;300MG
    • TABLET;ORAL - 150MG;150MG;200MG;EQ 10MG BASE
    Full View ScreenFull Screen View
    FDA Confirms Paragraph IV Patent Litigation for Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide Tablets
    FDA Confirms Paragraph IV Patent Litigation for Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide Tablets

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-elvitegravir-cobicistat-emtricitabine-tenofovir-alafenamide-tablets-59973.pdf

    FDA
    15 Jun 2023
    Share Share
    Stribild (elvitegravir) Japan Tobacco v. Mylan Pharma
    Stribild (elvitegravir) Japan Tobacco v. Mylan Pharma

    https://insight.rpxcorp.com/litigation_documents/13210791

    PATENT LITIGATION
    29 Jan 2019
    Share Share
    California reports show drug spending changes as 2 companies sue over disclosure
    California reports show drug spending changes as 2 companies sue over disclosure

    https://www.statnews.com/pharmalot/2019/01/03/california-drug-prices-transparency-4/?utm_source=STAT+Newsletters&utm_campaign=b0cc66a241-Pharmalittle_COPY_01&utm_medium=email&utm_term=0_8cab1d7961-b0cc66a241-150630089

    Ed Silverman STAT NEWS
    03 Jan 2019
    Share Share
    China National Drug Administration Approves Gilead's Genvoya
    China National Drug Administration Approves Gilead's Genvoya

    http://www.gilead.com/news/press-releases/2018/8/china-national-drug-administration-approves-gileads-genvoya-elvitegravir-cobicistat-emtricitabine-and-tenofovir-alafenamide-a-single-tablet-regimen-for-the-treatment-of-hiv1-infection

    PRESS RELEASE
    06 Aug 2018
    Share Share
    Truvada® (emtricitabine & tenofovir disoproxil fumarate)elvitegravir, GS 9350 (cobicistat): ViiV Healthcare v. Gilead Sciences
    Truvada® (emtricitabine & tenofovir disoproxil fumarate)elvitegravir, GS 9350 (cobicistat): ViiV Healthcare v. Gilead Sciences

    https://www.pharmacompass.com/pdf/news/truvada-emtricitabine-tenofovir-disoproxil-fumarateelvitegravir-gs-9350-cobicistat-viiv-healthcare-v-gilead-sciences-1518416906.pdf

    PATENT LITIGATION
    07 Feb 2018
    Share Share
    Gilead’s genvoya shows significantly higher rates of virologic suppression
    Gilead’s genvoya shows significantly higher rates of virologic suppression

    http://www.pharmabiz.com/NewsDetails.aspx?aid=100403&sid=2

    PHARMABIZ
    15 Feb 2017
    Share Share
    The Glaxo-Gilead HIV Battle Could Be Epic
    The Glaxo-Gilead HIV Battle Could Be Epic

    http://seekingalpha.com/article/4033080-glaxo-gilead-hiv-battle-epic

    SEEKING ALPHA
    28 Dec 2016
    Share Share
    Gilead asks FDA to Expand Exclusivity for a Key HIV Drug
    Gilead asks FDA to Expand Exclusivity for a Key HIV Drug

    https://www.statnews.com/pharmalot/2016/10/20/gilead-fda-hiv/

    ED SILVERMAN STAT
    21 Oct 2016
    Share Share
    Gilead Sciences (Cobicistat; Elvitegravir; Emtricitabine; Tenofovir Alafenamide Fumarate) Approved In US
    Gilead Sciences (Cobicistat; Elvitegravir; Emtricitabine; Tenofovir Alafenamide Fumarate) Approved In US

    https://www.pharmacompass.com/pdf/news/gilead-sciences-cobicistat-elvitegravir-emtricitabine-tenofovir-alafenamide-fumarate-approved-in-us-1474376630.pdf

    FDA
    07 Sep 2016
    Share Share
    Gilead gains next-gen HIV approval from FDA as it looks to beat back competition
    Gilead gains next-gen HIV approval from FDA as it looks to beat back competition

    http://www.fiercebiotech.com/story/gilead-gains-next-gen-hiv-approval-fda-it-looks-beat-back-competition/2016-04-05

    Ben Adams FIERCE BIOTECH
    06 Apr 2016
    Share Share
    Gilead's latest HIV cocktail wins FDA approval with a blockbuster pedigree
    Gilead's latest HIV cocktail wins FDA approval with a blockbuster pedigree

    http://www.fiercebiotech.com/story/gileads-latest-hiv-cocktail-wins-fda-approval-blockbuster-pedigree/2016-03-01

    Damian Garde FIERCE BIOTECH
    01 Mar 2016
    Share Share
    EU clears single pill HIV therapy Genvoya
    EU clears single pill HIV therapy Genvoya

    http://www.pharmatimes.com/Article/15-11-24/EU_clears_single_pill_HIV_therapy_Genvoya.aspx

    Selina McKee PHARMATIMES
    25 Nov 2015
    Share Share
    NCE Exclusivity Challenges are hot! Hot! HOT! Ferring Lets Loose with the Latest Lawsuit Challenging Denial of NCE Exclusivity for Colon Cleansing Drug
    NCE Exclusivity Challenges are hot! Hot! HOT! Ferring Lets Loose with the Latest Lawsuit Challenging Denial of NCE Exclusivity for Colon Cleansing Drug

    http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2015/06/nce-exclusivity-challenges-are-hot-hot-hot-ferring-lets-loose-with-the-latest-lawsuit-challenging-de.html

    Kurt R. Karst FDA LAW BLOG
    08 Jun 2015
    Share Share
    Gilead's low-dose, high-impact HIV drug heads to the FDA
    Gilead's low-dose, high-impact HIV drug heads to the FDA

    http://www.bizjournals.com/sanfrancisco/blog/biotech/2015/04/gilead-gild-hiv-aids-taf-tenofovir.html

    Ron Leuty SAN FRANSISCO BUSINESS TIMES
    09 Apr 2015
    Share Share
    Gilead Reports Positive Results from Preclinical Study of Investigational TLR7 Agonist in SIV-Infected, Virally Suppressed Monkeys
    Gilead Reports Positive Results from Preclinical Study of Investigational TLR7 Agonist in SIV-Infected, Virally Suppressed Monkeys

    http://www.pharmabiz.com/NewsDetails.aspx?aid=86934&sid=2

    Press Release PHARMABIZ
    27 Feb 2015
    Share Share
    Gilead Announces Phase 3 Results for Investigational Once-Daily Single Tablet HIV Regimen Containing Tenofovir Alafenamide (TAF)
    Gilead Announces Phase 3 Results for Investigational Once-Daily Single Tablet HIV Regimen Containing Tenofovir Alafenamide (TAF)

    http://www.gilead.com/news/press-releases/2015/2/gilead-announces-phase-3-results-for-investigational-oncedaily-single-tablet-hiv-regimen-containing-tenofovir-alafenamide-taf

    Press Release GILEAD
    26 Feb 2015
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search